{"nctId":"NCT01814137","briefTitle":"A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily","startDateStruct":{"date":"2013-03"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":40,"armGroups":[{"label":"IDegAsp BID + IAsp OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart","Drug: insulin aspart"]},{"label":"IDeg OD + IAsp TID","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":[]},{"name":"insulin degludec","otherNames":[]},{"name":"insulin aspart","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HbA1c equal to or above 7.0% measured after 26 weeks of treatment in NN5401-3941 (NCT01680341), by central laboratory\n\nExclusion Criteria:\n\n* Uncontrolled or untreated severe hypertension defined as systolic blood pressure equal to or above 180 mmHg and/or diastolic blood pressure equal to or above 100 mmHg\n* Impaired liver function, defined as alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) equal to or above 2.5 times upper limit of normal\n* Impaired renal function defined as serum-creatinine equal to or above 125 micromol/L (equal to or above 1.4 mg/dL) for males and equal to or above 110 micromol/L (equal to or above 1.3 mg/dL) for females","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Haemoglobin)","description":"Change from baseline in HbA1c after 26 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.20"},{"groupId":"OG001","value":"-0.49","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Emergent Adverse Events (TEAEs)","description":"A treatment emergent adverse event was defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last dose of the trial product.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"45","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Hypoglycaemic Episodes","description":"Confirmed hypoglycaemic episodes were defined as episodes that are either:\n\n* severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or\n* biochemically confirmed by a PG value of \\<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"95","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes","description":"Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 00:01 and 05:59 hours inclusive. Confirmed hypoglycaemic episodes were defined as severe hypoglycaemic episodes and/or a measured PG below 3.1 mmol/L (below 56 mg/dL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG after 26 weeks of treatment. FPG was analysed on blood samples from fasting subjects which were analysed centrally.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.80","spread":"3.59"},{"groupId":"OG001","value":"-2.57","spread":"2.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":20},"commonTop":["Upper respiratory tract infection","Pyrexia","Diabetic retinopathy","Abdominal pain upper","Cough"]}}}